Denosumab is a monoclonal antibody targeting RANK ligand (RANKL). Evidence has implicated RANKL in the development of BRCA1-associated breast cancer and thus, its inhibition may reduce the risk of developing breast cancer in women with a germline BRCA1 mutation. Judy Garber, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, outlines the details of the upcoming BRCA-P Phase III prevention trial (NCT04711109) of denosumab in BRCA1 carriers. The randomized, double-blind, placebo-controlled trial will be run internationally, using breast cancer development as an endpoint to determine the risk reduction associated with denosumab use. This interview took place during the 17th St. Gallen International Breast Cancer Conference.

свернуть